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Introduction
The clinical management of women with mildly abnormal
Papanicolaou (Pap) smear results, including atypical
squamous cells of undetermined significance (ASCUS)
and low-grade squamous intraepithelial lesions (LSILs),
was a topic of considerable controversy [1–3] until the
reports of the Atypical Squamous Cells of Undetermined
Significance/Low-Grade Squamous Intraepithelial
Lesions Triage Study (ALTS) [4–9] and subsequent
consensus conferences [10]. ALTS was a US National
Cancer Institute-sponsored randomized, multicenter
clinical trial of the initial management of women with
mildly abnormal Pap smear results (ASCUS and LSIL).
It investigated three different treatment recommend-
ations: immediate colposcopy with directed biopsy,
follow-up with repeated cytology every 4–6 months with
colposcopy only in women with persistent abnormalities,
and triage with human papillomavirus (HPV) testing.
The ALTS demonstrated that women with ASCUS can
be safely triaged using HPV DNA testing; approximately
half of women who are HPV-negative do not require
colposcopy [5,8]. LSIL Pap results cannot be efficiently
triaged because too few are HPV-negative to make
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testing worthwhile [4,9]. On the basis of these results
[4,5,8,9] and another study [11], the consensus con-
ference sponsored by the American Society for
Colposcopy and Cervical Pathology (ASCCP) recom-
mended HPV testing as a viable option for managing
women with ASCUS Pap results, whereas women with
LSIL should be referred for colposcopy.
The design of this study was similar to our previous
report [12], using the Hybrid Capture I test, and was
conducted at the time of the development of the ALTS
protocol.
Materials and Methods
Women with mildly abnormal Pap results, either ASCUS
or LSIL, who were referred to the colposcopy clinic at the
Mackay Memorial Hospital from February 1998 were
subjected to concurrent repeat Pap smear, collection of
a cervical swab for HPV DNA testing, and colposcopy
directed biopsies.
At the time of the visit for colposcopy, patients
completed a questionnaire that recorded age, use of
contraceptives/tobacco, previous history of HPV-related
disease, age at first intercourse, total number of sexual
partners, and parity. Subjects were excluded if they had
a prior cytologic diagnosis of high-grade squamous
intraepithelial lesion (HSIL) or had been treated for
cervical intraepithelial neoplasia (CIN).
All cytologic diagnoses were reported according to
the 1988 Bethesda System [13]. ASCUS was defined
using the same criteria as ASC-US in the 2001 Bethesda
System [14]. To distinguish the initial Pap smear from
the follow-up smear performed concurrently with
colposcopy, we call the former the referral smear and
the latter the repeat smear. The pathologic diagnoses
are reported using CIN terminology: lesions without
histologic abnormalities and cases with negative
colposcopic finding are referred to as normal and biopsy
specimens revealing koilocytotic atypia as CIN1 in
accordance with CIN Classification [15]. The main
study end point was detection of histologically con-
firmed CIN2/3, chosen because there is general con-
sensus that these lesions are at high risk of progressing
to invasive cancer and require treatment. HPV testing,
Pap smear, and biopsy interpretations were performed
independently as a double-blind assay.
HPV DNA was assayed in our laboratory using Hybrid
Capture II (Digene, Gaithersburg, MD, USA) with only
the high-risk group of probes. These probes are designed
to detect HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59 and 68. The tests were carried out according
to the manufacturer’s instructions and results are given
as the ratio of light emission (RLU) from a sample to the
average of three concurrently tested positive control
specimens containing 1 pg/mL of HPV 16 DNA. An RLU
greater than or equal to 1.0, corresponding to at least
5,000 HPV DNA copies per test well, was considered
positive.
HPV DNA testing sensitivity was calculated using the
results of colposcopy-directed biopsy histology as the
criterion standard. Two neoplasia thresholds were
considered separately to be positive outcomes (CIN2/3
vs CIN1/normal or CINs vs normal). The Chi-squared
test was used to compare HPV test results and CIN
grading. Data for women with ASCUS and LSIL were
analyzed separately.
Results
Clinical findings
A total of 266 women were enrolled. They were aged 20
to 78 years and 85% were more than 30 years old. About
66.5% had had only one lifetime sexual partner and
most had their first sexual intercourse in their twenties.
For 221 women (83.1%), the referral Pap result was the
first abnormal finding; they had no history of previous
HPV-related diseases. Therefore, these study subjects
were similar to the screen population in our previous
report [12]. Of the 266 women, 160 showed ASCUS
and 106 had LSIL.
Histologic diagnoses and HPV test results
Of the 160 women with ASCUS, 65% (104) showed
satisfactory negative colposcopy or benign biopsy
findings, 18.1% (29) had CIN1, and 16.9% (27) had
CIN2/3 (35% CIN biopsy rate) (Table 1). None had
invasive carcinoma. Among women with ASCUS, 88
(55%) tested positive for HPV. In the HPV-positive
group, 48.9% were disease-free by colposcopy or
biopsy, 21.6% had CIN1, and 29.5% had CIN2/3 on
biopsy (approximately 50% CIN overall). Of the 72
women who tested negative, 84.7% were disease-
free, whereas 13.9% had CIN1 on biopsy; only one case
(1.4%) had CIN2/3. The Hybrid Capture II test was
positive in 96.2% of cases with biopsy-proven CIN2/3
and 65.5% of women with biopsy-proven CIN1. There
was a significant increase in the HPV DNA-positive rate
as the punch biopsy grade increased from normal to
high-grade CIN (p < 0.01) (Table 1).
Table 2 shows the results of colposcopy-directed
biopsy for women with LSIL: 38.7% (41/106) showed
satisfactory negative colposcopy or benign biopsy
findings, 32.1% (34) had CIN1, and 29.2% (31) had
CIN2/3 (61% CIN). There were no cases of
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adenocarcinoma in situ or invasive carcinoma in this
series.
Of the 106 women with LSIL, 94 (88.7%) tested
positive for HPV. In the HPV-positive group, 35.1% were
normal by colposcopy or biopsy, 31.9% had CIN1, and
33% had CIN2/3 on biopsy. Of the 12 women who
tested negative, eight were disease-free, four had CIN1,
and none had CIN2/3. The Hybrid Capture II test was
positive in 100% of cases with biopsy-proven CIN2/3,
88.2% of women with biopsy-proven CIN1, and 80.4%
of disease-free women.
Table 3 shows the sensitivity, positive predictive
value, and referral rate for colposcopy based on a single
Hybrid Capture II result for detecting underlying
(concurrent) CIN2/3 in women with ASCUS and LSIL.
By definition, colposcopic biopsy was 100% sensitive
for detecting CIN2/3 or invasive carcinoma. Based on a
single baseline Hybrid Capture II test as triage, 55%
of women with ASCUS on the referral Pap smear would
have been referred for colposcopic biopsy with a
sensitivity and positive predictive value of 96.3% and
29.5%, respectively, while 88.7% of women with LSIL
on the referral smear would have been referred for
colposcopic biopsy with a sensitivity and positive
predictive value of 100% and 32.9%, respectively. A
single repeat Pap smear as triage (referral to colposcopy
for another ASCUS or worse cytologic finding) had
a sensitivity for CIN2/3 of 77.3% in all women with
ASCUS or LSIL on the referral Pap smear (data not
shown).
Discussion
Controversy exists regarding the proper evaluation
and management of LSIL and ASCUS cervical Pap results
[1–3]. Individually, these women are at lower risk for
CIN2/3 and cancer than those with HSIL, which has a
high positive predictive value for CIN2/3 and cancer, yet
their numerical dominance ensures that they account
for most cases of CIN2/3, a true cancer precursor [16].
To resolve this dilemma, a management guideline has
been produced by the ASCCP-sponsored consensus
conference [10], based mostly on both the new Bethesda
Table 1. Results of human papillomavirus (HPV) DNA testing and colposcopy for women with atypical
squamous cells of undetermined significance
Final diagnosis HPV DNA (–), n HPV DNA (+), n Total, n HPV DNA (+), %
Normal 61 43 104 41.3
CIN1 10 19 029 65.5
CIN2/3 01 26 027 96.3
Total 72 88 160 55.0
CIN = cervical intraepithelial neoplasia.
Table 2. Results of human papillomavirus (HPV) DNA testing and colposcopy for women with low-grade
squamous intraepithelial lesions
Final diagnosis HPV DNA (–), n HPV DNA (+), n Total, n HPV DNA (+), %
Normal 08 33 041 80.5
CIN1 04 30 034 88.2
CIN2/3 00 31 031 100
Total 12 94 106 88.7
CIN = cervical intraepithelial neoplasia.
Table 3. Sensitivity and positive predictive value (PPV) of baseline human papillomavirus (HPV) DNA testing
for detecting cervical intraepithelial neoplasia (CIN) 2/3
HPV DNA Positive Referral rate of colposcopy based
CIN2/3, n
CIN2/3 with
Sensitivity, % PPV, %
testing tests, n on baseline HPV DNA (+), % positive test, n
ASCUS (n = 160) 88 55.0 27 26 96.3 29.5
LSIL (n = 106) 94 88.7 31 31 100 32.9
ASCUS = atypical squamous cells of undetermined significance; LSIL = low-grade squamous intraepithelial lesion.
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terminology [14] and the ALTS data from the USA [4,5,
8,9,17,18]. The new guidelines recommend that women
with ASCUS can be safely managed by conventional
methods (repeat Pap test, immediate colposcopy, or
HPV testing), but that the preferred management
approach, after liquid-based cytology or when co-
collection of HPV DNA is available, is reflex HPV DNA
testing. In contrast, use of HPV testing for the triage of
women with LSIL is not presently recommended because
of the very high rate of HPV positivity in women with
LSIL, and colposcopy is the preferred management
modality.
In this study, we showed that the overall prevalence
of biopsy-confirmed CIN2/3 (an end-point disease that
should be identified and treated) was 16.9% and of
CIN1 was 18.1% in women with ASCUS. These findings
are similar to those in our previous report [19], which
identified concurrent CIN2/3 or worse in 15% of women
with ASCUS. Previous studies have shown that 20–38%
of ASCUS changes are associated with CIN at colpo-
scopic examination, but the vast majority of these are
CIN1, with CIN2/3 in 10% or less [5,11,16,20,21]. The
variation in prevalence of CIN is due to reproducibility
of ASCUS interpretation, study population, and
consensus histology diagnosis. The prevalence of
histologically confirmed CIN2/3 was 11.4% in women
with ASCUS in ALTS, which is comparable with our
results. However, the high percentage of ASCUS cases
found to have CIN2/3 on biopsy in our study may be
inflated by two differences in study methods. First, we
did not overuse the ASCUS category in place of benign
cellular changes. On the contrary, we may have assigned
smears as ASCUS when more should have been classified
as LSIL. Secondly, the Kaiser Permanente [11,16] and
the ALTS [5] investigators defined CIN2/3 from
consensus review by expert pathologists, while in our
study, a single pathologist made the diagnosis, giving
significantly more severe interpretations than review by
quality control pathologists would have done [22].
Despite the lower risk for each individual given this
diagnosis, the disease lesion likely to progress is there in
a small number of women, to be missed or detected,
within a majority of women who are normal or who will
have eventual lesion regression. Therefore, the clinical
dilemma is how to best find the 10–15% of smears that
are cancer precursors without unnecessary evaluation
of most unimportant or nonexistent disease.
Among women referred with ASCUS in our study,
the proportion with HPV positivity, the sensitivity of
detecting CIN2/3, and the referral rate for colposcopy
based on a single baseline Hybrid Capture II test as
intermediate triage are consistent with the findings
from ALTS enrollment data [5]. HPV testing allows clear
and objective statements regarding the meaning of
ASCUS interpretation. Approximately half of all women
with ASCUS will be high-risk HPV DNA-negative and
can be rapidly reassured that their smears are benign
look-alikes related to immature metaplasia, reactive
changes, atrophy, or HPV types unrelated to cancer risk
[23], but have a 1.4% chance of having CIN2/3 (this
study) that should, theoretically, be identified in subse-
quent follow-up [8,19]. For women who are high-risk
HPV DNA-positive, the designation “undetermined”
should be changed to HPV-related. Approximately half
of Hybrid Capture II test-positive women with ASCUS
actually had a lesion (CIN), and approximately one-
third had a chance of having CIN2/3 in our study.
In an effort to maximize sensitivity, ASCUS is used as
the threshold for referral for colposcopy in our clinical
practice, as in the USA. Colposcopy combined with
directed biopsy is the standard diagnostic procedure
for evaluating the cervix and has been presumed to
be highly sensitive and accurate. In settings where
colposcopy is unavailable, Hybrid Capture II testing is
an option to manage women with ASCUS according to
consensus guidelines based on ALTS results [5,8,10].
International variation in cytology terminology, com-
pounded by the use of different morphologic criteria for
similarly termed diagnoses, might suggest that ALTS
results cannot be generalized to settings outside the
USA [24]. However, the presented parameters based on
a single Hybrid Capture II test (the proportion of HPV
positivity, sensitivity, and negative predictive value for
detecting CIN2/3, the prevalence of biopsy-confirmed
CIN, and the distribution of HPV positivity among
different histologic diagnoses) are comparable with
those of ALTS [5] and another important study [11],
except for the higher prevalence of CIN2/3 in our study.
This reconfirms the good reproducibility of our cytologic
interpretation and the objectivity of the Hybrid Capture
II test. We do not recommend repeat Pap smear as
follow-up for women with ASCUS because the sensitivity
of a single repeat Pap smear for detecting CIN2/3 is
unsatisfactory since liquid-based cytology is uncommon
in Taiwan, and 50% of women who underwent this test
were lost to follow-up in our previous study [19]. The
decision to use Hybrid Capture II testing as an
intermediate step in evaluating ASCUS as opposed to
immediate referral for colposcopy may, therefore, be
based primarily on economic considerations. HPV triage
is geared for a population that can afford both liquid-
based cytology and HPV testing. In the USA, the projected
savings from the reduction in colposcopies and
immediate follow-up visits theoretically outweigh the
additional costs of the tests. In Taiwan, this approach
would be much too expensive [19].
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In women with LSIL referred for colposcopic
evaluation, case series show a variable rate of biopsy-
confirmed CIN2/3, typically between 15% and 30% [9,
16,25]. The diagnosis of CIN2/3 at the time of
colposcopy-directed biopsy in our study was approxi-
mately 30%, which is consistent with our previous
report of 239 women with LSIL [19]. Although this may
be explained in part by the high intraobserver and
interobserver variability associated with the cytologic
interpretation of LSIL, it was mainly due to lack of
consensus histologic diagnoses in our study. In ALTS,
the cytologic diagnosis of LSIL appeared to be more
reproducible than other cytologic diagnoses (ASCUS
and HSIL), and data also suggest that 41% of CIN1
diagnoses are inflated [22]. It appeared that over-
interpretation of CIN1 did not occur in our series since
approximately 90% of biopsy-proven CIN1 and all
CIN2/3 were HPV-positive.
Specifically, LSIL cytomorphologic patterns all reflect
infection with HPV. The percentage of LSIL diagnoses
that were HPV-positive in this study (almost 90%) did
not differ substantially from that in ALTS [4], which
implies tremendous specificity in LSIL cytologic diag-
nosis. If one accepts the thesis that all LSIL patients are
HPV-positive, then the correlation between cytologic
diagnosis and HPV positivity provides independent
quality assurance of diagnostic certainty. This reconfirms
good reproducibility of cytologic interpretation of LSIL
among cytopathologists who participated in ALTS [4]
and this study. Approximately one-third of women with
LSIL had CIN1 and another one-third had CIN2/3.
Based on the fair reproducibility of LSIL interpretation
and that most LSIL cases were oncogenic HPV-positive
in our study, which is consistent with ALTS [4,9], the use
of Hybrid Capture II testing for triage in women with
LSIL is limited. Although some authors advocate
cytological surveillance at 4–6-month intervals in women
with LSIL [26–28], performing colposcopy when
indicated by repeat abnormal cytology (ASCUS plus),
which may conserve resources by lessening the number
of colposcopic examinations needed and may decrease
over-treatment of transient lesions that ordinarily would
regress on their own [25,26], there are risks associated
with this approach, including noncompliance with
follow-up, a high prevalence of biopsy-confirmed
CIN2/3, and infrequent invasive carcinoma during
follow-up [26,27]. Data from our previous report sup-
port this observation: 48% of patients with LSIL were
lost to follow-up and a high percentage of women with
LSIL had concurrent CIN2/3 [19]. We prefer immediate
colposcopy in women with LSIL.
With the ALTS from the USA and the HART study
(HPV in Addition to Routine Testing) from the UK [29],
the community now has a clear and useful tool to
objectively compare cytologic interpretations with
predicted outcomes. HPV testing (Hybrid Capture II),
as demonstrated in our study, has low interlaboratory/
interobserver variability for cervical cytology, especially
ASCUS. It is, therefore, an efficient and sensitive
management option for women with an equivocal Pap
smear. HPV-positive ASCUS is clinically equivalent to
LSIL, with similar risks of concurrent and subsequent
occurrence (either missed prevalent disease or incident
disease) of CIN2/3, as suggested in ALTS [17,18]. Our
data are consistent with this thesis, in that approximately
one-third of women with HPV-positive ASCUS or LSIL
had concurrent CIN2/3, although there were more
cases of negative colposcopy or normal histology among
HPV-positive ASCUS smears and more CIN1 in LSIL
smears. Since the sensitivity of colposcopy is not perfect
for detecting CIN2/3, as previously presumed [8,9], the
efficient follow-up of women without CIN2/3 after
initial colposcopic evaluation should be identical [17].
In conclusion, a cytologic diagnosis of LSIL had
good reproducibility in our study, which always means
HPV infection. The HPV test is not appropriate for initial
evaluation of women with LSIL. It is clear that the HPV
test (Hybrid Capture II) can effectively differentiate
women with ASCUS who are likely to have CIN2/3 from
those who are not. Women with HPV-positive ASCUS/
LSIL have a one-third chance of having CIN2/3 at the
time of initial colposcopy-directed biopsy.
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